Condition: Breast Neoplasms · Breast Cancer · Sponsor: Merck Sharp & Dohme LLC
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus ( Site 0057) | Aurora, Colorado, United States | Recruiting |
| Dana-Farber Cancer Institute ( Site 0050) | Boston, Massachusetts, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey ( Site 0052) | New Brunswick, New Jersey, United States | Recruiting |
| Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053) | Greenville, South Carolina, United States | Recruiting |
| Inova Schar Cancer Institute ( Site 0051) | Fairfax, Virginia, United States | Recruiting |
| Kingston General Hospital ( Site 0061) | Kingston, Ontario, Canada | Recruiting |
| Princess Margaret Cancer Centre ( Site 0001) | Toronto, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Université de Montréal ( Site 0004) | Montreal, Quebec, Canada | Recruiting |
| Jewish General Hospital ( Site 0003) | Montreal, Quebec, Canada | Recruiting |
| Rambam Health Care Campus ( Site 0011) | Haifa, Israel | Recruiting |
| Rabin Medical Center ( Site 0012) | Petah Tikva, Israel | Recruiting |
| Sheba Medical Center ( Site 0010) | Ramat Gan, Israel | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06686394